Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Yu, Yi ^a,b,c   Zhang, Mingxing ^a,b,c   Zhang, Xiaoyan ^a,b,c   Cai, Qingqing ^a,b,c   Hong, Shanshan ^a,b,c   Jiang, Wei ^a,b,c   Xu, Congjian ^a,b,c  

^a OBSTETRICS AND GYNECOLOGY HOSPITAL OF FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Combined targeting; Epidermal growth factor receptor (EGFR); Ovarian cancer; Platelet activating factor receptor (PAFR); Signal pathway

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; APAFANT; EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; THROMBOCYTE ACTIVATING FACTOR RECEPTOR;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL COUNTING; CELL COUNTING KIT 8; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DIAGNOSTIC KIT; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; FEMALE; FILTERS AND MEMBRANES; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; IMMUNOASSAY; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; ISOBOLOGRAM ANALYSIS; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AZEPINES; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PLATELET AGGREGATION INHIBITORS; PLATELET MEMBRANE GLYCOPROTEINS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TRIAZOLES; TYRPHOSTINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901333058     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-7-39     Document Type: Article

References (38)

1. PARP inhibition in BRCA-mutated breast and ovarian cancers. Chan SL, Mok T, Lancet 2010 376 211 213 10.1016/S0140-6736(10)61119-1 20656109
2. Weekly paclitaxel in the treatment of recurrent ovarian cancer. Baird RD, Tan DSP, Kaye SB, Nat Rev Clin Oncol 2010 7 575 582 10.1038/nrclinonc.2010.120 20683437
3. Targeting signaling pathways in epithelial ovarian cancer. Smolle E, Taucher V, Pichler M, Petru E, Lax S, Haybaeck J, Int J Mol Sci 2013 14 9536 9555 10.3390/ijms14059536 23644885
4. EGFR and cancer prognosis. Nicholson RI, Gee JMW, Harper ME, Eur J Cancer 2001 37 9 S15 11597399
5. Epidermal growth-factor receptor (egfr) expression in nonsmall cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph-nodes in the squamous subtype. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi H, Angeletti CA, Pingitore R, Pepe S, Basolo F, Bevilacqua G, Eur J Cancer 1995 31A 178 183 7718322
6. Epidermal growth factor receptor: mechanisms of activation and signalling. Jorissen RN, Walker F, Pouliot N, Garrett TPJ, Ward CW, Burgess AW, Exp Cell Res 2003 284 31 53 10.1016/S0014-4827(02)00098-8 12648464 (Pubitemid 36331965)
7. EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Turner T, Chen P, Goodly LJ, Wells A, Clin Exp Metastasis 1996 14 409 418 10.1007/BF00123400 8878415 (Pubitemid 26363215)
8. Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. Ahmed N, Maines-Bandiera S, Quinn MA, Unger WG, Dedhar S, Auersperg N, Am J Physiol Cell Physiol 2006 290 1532 C1542 10.1152/ajpcell.00478.2005 16394028 (Pubitemid 43830793)
9. A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Casanova ML, Larcher F, Casanova B, Murillas R, Fernandez-Acenero MJ, Villanueva C, Martinez-Palacio J, Ullrich A, Conti CJ, Jorcano JL, Cancer Res 2002 62 3402 3407 12067982 (Pubitemid 34651386)
10. Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Lu ZM, Jiang GQ, Blume-Jensen P, Hunter T, Mol Cell Biol 2001 21 4016 4031 10.1128/MCB.21.12.4016-4031.2001 11359909 (Pubitemid 32476463)
11. Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer. Hagemann AR, Novetsky AP, Zighelboim I, Gao F, Massad LS, Thaker PH, Powell MA, Mutch DG, Wright JD, Gynecol Oncol 2013 131 535 540 10.1016/j.ygyno.2013.09.032 24096113
12. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group study. Secord AA, Blessing JA, Armstrong DK, Rodgers WH, Miner Z, Barnes MN, Lewandowski G, Mannel RS, Gynecol Oncol 2008 108 493 499 10.1016/j.ygyno.2007.11.029 18191993
13. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK, Gynecol Oncol 2009 113 21 27 10.1016/j.ygyno.2008.12.003 19162309
14. The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer. Palayekar MJ, Herzog TJ, Int J Gynecol Cancer 2008 18 879 890 10.1111/j.1525-1438.2007.01144.x 18053062
15. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Seiden MV, Burris HA, Matulonis U, Hall JB, Armstrong DK, Speyer J, Weber JDA, Muggia F, Gynecol Oncol 2007 104 727 731 10.1016/j.ygyno.2006.10.019 17126894
16. Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). Pautier P, Joly F, Kerbrat P, Bougnoux P, Fumoleau P, Petit T, Rixe O, Ringeisen F, Carrasco AT, Lhomme C, Gynecol Oncol 2010 116 157 162 10.1016/j.ygyno.2009.10.076 20109725
17. Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma. Hirte HW, Oncotargets Ther 2013 6 427 435
18. Unexpected gastrointestinal toxicity from Docetaxel/Carboplatin/Erlotinib followed by maintenance Erlotinib treatment for newly diagnosed stage III/IV ovarian cancer, primary peritoneal, or fallopian tube cancer. Holmberg LA, Goff B, Veljovich D, Gynecol Oncol 2011 121 426 426 10.1016/j.ygyno.2010.11.049 21324515
19. Trastuzumab sensitizes ovarian cancer cells to EGFR-targeted therapeutics. Wilken JA, Webster KT, Maihle NJ, J Ovarian Res 2010 3 7 10.1186/1757-2215-3-7 20346177
20. Activation of platelet-activating factor receptor and pleiotropic effects on tyrosine phospho-EGFR/Src/FAK/paxillin in ovarian cancer. Aponte M, Jiang W, Lakkis M, Li M-J, Edwards D, Albitar L, Vitonis A, Mok SC, Cramer DW, Ye B, Cancer Res 2008 68 5839 5848 10.1158/0008-5472.CAN-07-5771 18632638
21. Ovarian cancer G protein coupled receptor 1 suppresses cell migration of MCF7 breast cancer cells via a Galpha12/13-Rho-Rac1 pathway. Li J, Guo B, Wang J, Cheng X, Xu Y, Sang J, J Mol Signal 2013 8 6 6 10.1186/1750-2187-8-6 23663350
22. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. O'Hayre M, Vazquez-Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S, Gutkind JS, Nat Rev Cancer 2013 13 412 424 10.1038/nrc3521 23640210
23. Molecular signatures of G-protein-coupled receptors. Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM, Nature 2013 494 185 194 10.1038/nature11896 23407534
24. Inhibition of EGF/EGFR activation with naphtho 1,2-b furan-4,5-dione blocks migration and invasion of MDA-MB-231 cells. Hsieh C-Y, Tsai P-C, Tseng C-H, Chen Y-l, Chang L-S, Lin S-R, Toxicol in Vitro 2013 27 1 10 10.1016/j.tiv.2012.10.001 23064031
25. Inhibition by platelet-activating factor of Src- and hepatocyte growth factor-dependent invasiveness of intestinal and kidney epithelial cells-Phosphatidylinositol 3 ′-kinase is a critical mediator of tumor invasion. Kotelevets L, Noe V, Bruyneel E, Myssiakine E, Chastre E, Mareel M, Gespach C, J Biol Chem 1998 273 14138 14145 10.1074/jbc.273.23.14138 9603913 (Pubitemid 28319121)
26. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Chou TC, Talalay P, Adv Enzyme Regul 1984 22 27 55 6382953
27. Implications of EGFR inhibition in ovarian cancer cell proliferation. Bull Phelps SL, Schorge JO, Peyton MJ, Shigematsu H, Xiang L-L, Miller DS, Lea JS, Gynecol Oncol 2008 109 411 417 10.1016/j.ygyno.2008.02.030 18423824
28. Anti-EGFR therapy: mechanism and advances in clinical efficacy in breast cancer. Flynn JF, Wong C, Wu JM, J Oncol 2009 2009 526963 526963 19390622
29. Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Sherwood ER, Van Dongen JL, Wood CG, Liao S, Kozlowski JM, Lee C, Br J Cancer 1998 77 855 861 10.1038/bjc.1998.142 9528825 (Pubitemid 28101770)
30. The environmental stressor ultraviolet B radiation inhibits murine antitumor immunity through its ability to generate platelet-activating factor agonists. Sahu RP, Turner MJ, DaSilva SC, Rashid BM, Ocana JA, Perkins SM, Konger RL, Touloukian CE, Kaplan MH, Travers JB, Carcinogenesis 2012 33 1360 1367 10.1093/carcin/bgs152 22542595
31. Activated networking of platelet activating factor receptor and FAK/STAT1 induces malignant potential in BRCA1-mutant at-risk ovarian epithelium. Zhang L, Wang D, Jiang W, Edwards D, Qiu W, Barroilhet LM, Rho J-H, Jin L, Seethappan V, Vitonis A, Wang J, Mok SC, Crum C, Cramer DW, Ye B, Reprod Biol Endocrinol 2010 8 74 10.1186/1477-7827-8-74 20576130
32. Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor. Ishii S, Nagase T, Tashiro F, Ikuta K, Sato S, Waga I, Kume K, Miyazaki J, Shimizu T, EMBO J 1997 16 133 142 10.1093/emboj/16.1.133 9009274 (Pubitemid 27032856)
33. Emerging roles of PAR-1 and PAFR in melanoma metastasis. Melnikova VO, Villares GJ, Bar-Eli M, Cancer Microenviron 2008 1 103 111 10.1007/s12307-008- 0002-7 19308689
34. Transcriptional control of melanoma metastasis: The importance of the tumor microenvironment. Braeuer RR, Zigler M, Villares GJ, Dobroff AS, Bar-Eli M, Semin Cancer Biol 2011 21 83 88 10.1016/j.semcancer.2010.12.007 21147226
35. Expression of PAFR as part of a prosurvival response to chemotherapy: a novel target for combination therapy in Melanoma. Onuchic AC, Machado CML, Saito RF, Rios FJ, Jancar S, Chammas R, Mediat Inflamm 2012 2012 175408
36. Transduction of receptor signals by beta-arrestins. Leftowitz RJ, Shenoy SK, Science 2005 308 512 517 10.1126/science.1109237 15845844 (Pubitemid 40570575)
37. GRKs and arrestins: regulators of migration and inflammation. Vroon A, Heijnen CJ, Kavelaars A, J Leukoc Biol 2006 80 1214 1221 10.1189/jlb.0606373 16943386 (Pubitemid 44904958)
38. Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Luttrell LM, Roudabush FL, Choy EW, Miller WE, Field ME, Pierce KL, Lefkowitz RJ, Proc Natl Acad Sci USA 2001 98 2449 2454 10.1073/pnas.041604898 11226259 (Pubitemid 32209502)